IL286416A - Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration - Google Patents

Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration

Info

Publication number
IL286416A
IL286416A IL286416A IL28641621A IL286416A IL 286416 A IL286416 A IL 286416A IL 286416 A IL286416 A IL 286416A IL 28641621 A IL28641621 A IL 28641621A IL 286416 A IL286416 A IL 286416A
Authority
IL
Israel
Prior art keywords
abiraterone
administration
formation
methods
pharmaceutical formulations
Prior art date
Application number
IL286416A
Other languages
English (en)
Hebrew (he)
Original Assignee
Dispersol Tech
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dispersol Tech, Univ Texas filed Critical Dispersol Tech
Publication of IL286416A publication Critical patent/IL286416A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL286416A 2019-03-18 2021-09-14 Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration IL286416A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820076P 2019-03-18 2019-03-18
US201962942111P 2019-11-30 2019-11-30
PCT/US2020/023066 WO2020190900A1 (en) 2019-03-18 2020-03-17 Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof

Publications (1)

Publication Number Publication Date
IL286416A true IL286416A (en) 2021-10-31

Family

ID=72521270

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286416A IL286416A (en) 2019-03-18 2021-09-14 Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration

Country Status (9)

Country Link
US (1) US20220362264A1 (https=)
EP (1) EP3941478A4 (https=)
JP (1) JP2022525425A (https=)
CN (1) CN113825514A (https=)
AU (1) AU2020240017A1 (https=)
BR (1) BR112021018540A2 (https=)
CA (1) CA3133620A1 (https=)
IL (1) IL286416A (https=)
WO (1) WO2020190900A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101738369B1 (ko) * 2009-07-22 2017-05-22 그뤼넨탈 게엠베하 핫 멜트 압출된 제어 방출 투여형
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
EP3247334A1 (en) * 2015-01-20 2017-11-29 Merck Patent GmbH Solid dispersions of compounds using polyvinyl alcohol as a carrier polymer
WO2017037647A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical compositions of abiraterone
TWI717629B (zh) * 2017-08-28 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 Cyp17抑制劑的藥物組合物及其製備方法
WO2019060525A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF CYCLIC OLIGOMER AND ABIRATERONE AND METHODS OF FORMATION AND ADMINISTRATION THEREOF

Also Published As

Publication number Publication date
AU2020240017A1 (en) 2021-11-04
US20220362264A1 (en) 2022-11-17
BR112021018540A2 (pt) 2021-11-30
WO2020190900A1 (en) 2020-09-24
EP3941478A1 (en) 2022-01-26
JP2022525425A (ja) 2022-05-13
EP3941478A4 (en) 2022-12-28
WO2020190900A8 (en) 2021-10-14
CN113825514A (zh) 2021-12-21
CA3133620A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
IL273125A (en) Pharmaceutical formulations of cyclic oligomer of abiraterone and methods of making and taking them
IL275704A (en) Pharmaceutical formulation for oral administration containing cannabinoids and poloxamer
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
EP4335517B8 (en) Administration and dosage of diaminophenothiazines
IL283522A (en) Pharmaceutical preparations containing anti-191p4d12 antibody drug conjugates and methods of using them
IL283938B2 (en) History of oxypyrimidinyl-methyl-benzamide and their deuterated forms and pharmaceutical preparations containing them
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EP3600259A4 (en) NEW PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBINE AND DERIVATIVES THEREOF AND METHODS FOR THE MANUFACTURE AND USE OF THEM
ZA201906274B (en) Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
IL286416A (en) Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration
MX2022013450A (es) Formulaciones farmaceuticas.
SG11202108280RA (en) Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
EP3532052A4 (en) DESIGN AND COMPOSITION OF CELL-STABILIZED PHARMACEUTICAL FORMULATIONS
MA55625A (fr) Compositions et méthodes d'administration de produits thérapeutiques
SG11202112530VA (en) Pharmaceutical composition of a weak acid drug and methods of administration
EP3277663A4 (en) Novel drug delivery conjugated moiety for oral administration of drug unsuitable for oral administration and preparation method thereof
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
IL283405A (en) Formulations, methods, kits and dosage forms to improve the stability of an active medicinal component
GB201910294D0 (en) Liquid pharmaceutical composition for oral administration comprising paracetamol and codeine phosphate
EP3681604A4 (en) SURFACE PREPARATION ORAL FOR THE PREVENTION OF DISEASES ACQUIRED THROUGH THE ORAL CAVITY AND PHARYNX
ZA202005701B (en) Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
ES3064824T3 (en) Pharmaceutical formulations of bictegravir and lenacapavir
WO2019151966A3 (en) Pharmaceutical tablet compositions of dabigatran
MX2019008847A (es) Profarmacos de cisteamina.
AU2019903522A0 (en) Pharmaceutical Compositions and Methods of Use